- Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
- Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film
- Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024
- Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
- Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference
- Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
- Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
- Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
- Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
More ▼
Key statistics
On Wednesday, Aquestive Therapeutics Inc (AQST:NMQ) closed at 2.41, 92.58% above the 52 week low of 1.25 set on Oct 06, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.41 |
---|---|
High | 2.44 |
Low | 2.36 |
Bid | 2.39 |
Offer | 2.45 |
Previous close | 2.42 |
Average volume | 2.75m |
---|---|
Shares outstanding | 91.04m |
Free float | 86.46m |
P/E (TTM) | -- |
Market cap | 219.40m USD |
EPS (TTM) | -0.4273 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼